Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection
Objectives: To assess the efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine; GPO-vir □ in advanced HIV infection. Material and Method: Open-label combined prospective and retrospective study involving 102 HIV infected patients with baseline CD4cell count &...
Saved in:
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/23540 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.23540 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.235402018-08-20T14:09:35Z Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection Aneley Getahun Somsit Tansuphasawadikul Varunee Desakorn Jittima Dhitavat Punnee Pitisuttithum Mahidol University Bamrasnaradura Infectious Disease Institute Medicine Objectives: To assess the efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine; GPO-vir □ in advanced HIV infection. Material and Method: Open-label combined prospective and retrospective study involving 102 HIV infected patients with baseline CD4cell count < 100 cells/mm 3. All patients received GPO-vir □ for 48 weeks. The CD4 cell count and plasma viral load (pVL) was measured at 48 weeks. Results: The median baseline CD4 cell count and pVL were 13 cells/mm 3 and 363,500 copies/ml, respectively. At 48 weeks, the median CD4 cell count increased to191 cells/mm 3 and 63.7% in intention-to treat and 82.3% in on-treatment analysis had pVL < 50 copies/ml. There was no significant difference in pVL between patients with baseline pVL > 100,000 or ≤ 100,000 copies/ml (p = 0.312). The incidence of hepatotoxicity, rash and peripheral neuropathy was 4.9%, 14.7% and 6.9%, respectively. Conclusion: GPO-vir □ was well tolerated and effective in increasing CD4 cell count and suppressing plasma viremia in advanced HIV infection during the 48 weeks follow-up period. 2018-08-20T07:09:35Z 2018-08-20T07:09:35Z 2006-10-11 Article Journal of the Medical Association of Thailand. Vol.89, No.9 (2006), 1472-1478 01252208 01252208 2-s2.0-33749447838 https://repository.li.mahidol.ac.th/handle/123456789/23540 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33749447838&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Aneley Getahun Somsit Tansuphasawadikul Varunee Desakorn Jittima Dhitavat Punnee Pitisuttithum Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection |
description |
Objectives: To assess the efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine; GPO-vir □ in advanced HIV infection. Material and Method: Open-label combined prospective and retrospective study involving 102 HIV infected patients with baseline CD4cell count < 100 cells/mm 3. All patients received GPO-vir □ for 48 weeks. The CD4 cell count and plasma viral load (pVL) was measured at 48 weeks. Results: The median baseline CD4 cell count and pVL were 13 cells/mm 3 and 363,500 copies/ml, respectively. At 48 weeks, the median CD4 cell count increased to191 cells/mm 3 and 63.7% in intention-to treat and 82.3% in on-treatment analysis had pVL < 50 copies/ml. There was no significant difference in pVL between patients with baseline pVL > 100,000 or ≤ 100,000 copies/ml (p = 0.312). The incidence of hepatotoxicity, rash and peripheral neuropathy was 4.9%, 14.7% and 6.9%, respectively. Conclusion: GPO-vir □ was well tolerated and effective in increasing CD4 cell count and suppressing plasma viremia in advanced HIV infection during the 48 weeks follow-up period. |
author2 |
Mahidol University |
author_facet |
Mahidol University Aneley Getahun Somsit Tansuphasawadikul Varunee Desakorn Jittima Dhitavat Punnee Pitisuttithum |
format |
Article |
author |
Aneley Getahun Somsit Tansuphasawadikul Varunee Desakorn Jittima Dhitavat Punnee Pitisuttithum |
author_sort |
Aneley Getahun |
title |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection |
title_short |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection |
title_full |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection |
title_fullStr |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection |
title_full_unstemmed |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection |
title_sort |
efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (gpo-vir □) in advanced hiv infection |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/23540 |
_version_ |
1763493140138819584 |